ETO-cell® 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung clinical trials

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)

This study is looking at new ways to treat a type of lung cancer that hasn't spread widely. It compares standard treatments with new drug combinations to see if they can stop the cancer from growing for longer. It aims to find the best treatment for patients with this type of lung cancer.